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The milk alkali syndrome was more commonly
seen when milk and absorbable alkalis were the
mainstays oftreatment ofsymptoms due to acid-
related upper gastro-intestinal disease. The
syndrome became rarer after the introduction of
the non-absorbable alkalis and H2 receptor
antagonists but it did not disappear altogether
and should always be suspected when patients
present with hypercalcaemia, renal impairment
and metabolic alkalosis. Calcium carbonate is
widely available in over-the-counter antacid
preparations and is used in the prophylaxis and
treatment of osteoporosis. An excessive intake
can cause the milk alkali syndrome and it is
possible that because of its increasing use more
cases ofthe milk alkali syndrome will be seen in
the future.
We report a case ofthe milk alkali syndrome in a
female who took excess calcium carbonate as
treatment for heartburn and vomiting. She was
treated with intravenous saline and diuretics and
made an apparently full recovery. She also
received disodium pamidronate but it is unlikely
that this contributed to her improvement.
CASEREPORT A34yearoldfemalepresented
in March 2001 with a short history ofheadache,
vomiting, dizzinessandlegpain.Thesesymptoms
startedafterthe suddendeathofherfather-in-law
two and a half weeks before. Her general
practitioner found the creatinine to be 466
micromols/l (normal 40-110) and CO2 to be 45
mmol/l (normal 22-30) and arranged for her
admission. Shehadahistoryofinactiveulcerative
colitis and ofheartburn and dyspepsia for which
she took 2 to 4 Rennie tablets (1.4 to 2.7 g of
calcium carbonate) per day. She drank
approximately twenty four units of alcohol a
week. Physical examination only showed
dehydration andbloodpressure of 180/98 mmHg
lying and 170/94 standing.
Investigations showed Hgb 11.6 g/dl (normal
11.5-16.5), WBC 7.0 x 109/l (normal 4.0-10.0),
CRP 8 mg/i (normal 0-10), Na 136 mmol/l
(normal 135-145), K 2.3 mmol/l (normal 3.5-
5.0), Cl 90 mmol/l (normal 98-108), CO2 38
mmol/l(normal22-30),urea 18.4mmol/1 (normal
3.3-8.8), creatinine 267 micromol/1 (normal 40-
110), corrected Ca 3.39 mmol/l (normal 2.10-
2.60), PO4 0.83 mmol/l (normal 0.85-1.55),
alkaline phosphatase 87 units/l (normal 35-120),
parathyroid hormone 13 pg/ml (normal 10-85),
and angiotensin converting enzyme 72 units/l
(normal 27-100). Protein electrophoresis was
normal and no Bence-Jones protein was found in
the urine. Ultrasound scan of abdomen showed
normal kidneys and renal tracts, and that ofneck
showednoenlargementoftheparathyroidglands.
X-rays of chest, hands, and skull were normal
and isotope bone scan was normal. A barium
meal as an outpatient showed mild gastro-
oesophageal reflux and some crico-pharyngeal
spasm.
She was treated with intravenous saline and
bumetanide and urine output increased from 20
mls/houronadmissionto amaximumof240 mls/
hour on day 6. The corrected calcium initially
showed little change and disodium pamidronate
was given on days 3, 4 and 5 (total dose 90 mg).
By day 7 the corrected calcium was 2.76 mmols/l
and creatine was 171 micromols/l. The blood
pressure settled without specific treatment. She
was questioned further about her calcium intake
and it was found that during the time that she had
beenunwellshehadbeentaking36Rennietablets
(24.5 g of calcium carbonate) per day. She was
discharged on day 9 with a corrected calcium of
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2.80mmols/lonnotreatmentotherthanranitidine.
She was advised not to take calcium-containing
antacids.
At the outpatient clinic she reported feeling well
withnoheartburn. Correctedcalciumwasnormal
by day 14 (2.48 mmols/l) and remained normal
thereafter. Theparathyroidhormone levelroseto
143 pg/ml on day 14, 163 pg/ml on day 25, and
114 pg/ml on day 63, before returning to normal
at60pg/mlonday 203. Creatinine wasnormalby
day 63 (95 micromols/l). No evidence of
malignancy was found on investigation and the
eventually normal calcium and parathyroid
hormone would be very much against primary
hyperparathyroidism. The final diagnosis was
one ofthe milk alkali syndrome.
DISCUSSION
Sippysuggestedin 1915 thatpatients withgastric
andduodenal ulceration shouldbe fed amilk and
creammixturehourlyduringthedayandbegiven
antacids hourly midway between feedings and in
the evenings.' Some patients on this treatment
developed headache, vomiting, dizziness and
muscle and joint pain, and in 1923 Hardt and
Rivers found that this subgroup had renal failure
and metabolic alkalosis.2 The hypercalcaemia
which is now known to be central to the milk
alkali syndrome was first described by Cope in
1936.3 Over the next forty years the milk alkali
syndrome was predominately a disease of men
with peptic ulceration who were treating
themselves with large amounts of milk and
sorbable alkali such as sodium bicarbonate.4 The
incidence of the syndrome fell following the
introduction of modern treatments and in the
years 1985 to 1989 it averaged 2% ofall patients
admitted with hypercalcaemia.4 Over the
following four years, however, the incidence
rose to an average of 12%, that for 1993 alone
being 38%. The majority of patients in the later
yearswerefemaleandtheircalciumsourcetended
to be calcium carbonate rather than milk.
Biochemicalevidenceforthischangewas seenin
a reduction in average phosphate concentration
atpresentation-milkcontainsphosphate,calcium
carbonate does not.4
Calcium carbonate is a popular and effective
antacidwhichisreadilyavailableoverthecounter.
It is increasingly being promoted and prescribed
for osteoporosis and other conditions. In limited
amounts it is not toxic. It is poorly soluble in
water but does dissolve in hydrochloric acid so
thatalthough only 1% ofadoseis absorbedwhen
gastric acid is lacking, 17% is absorbed when
gastric acid is present.5 Those who have had the
milk alkali syndrome do not absorb more than
normal controls. The lowest dose of calcium
carbonate required to produce the milk alkali
syndrome is probably around 10 g (4 g elemental
calcium) per day. Individual susceptibility is
dependent on factors such as pre-existing renal
diseaseandconcomitanttreatmentwiththiazides.6
Ourpatient was taking 24.5 g perday (36 Rennie
tablets), adosejustovertwicethemanufacturer's
recommended daily maximum of 16 Rennie
tabletsperday (10.9gofcalciumcarbonate). The
milkalkalisyndromeisnotlistedasacomplication
on the product packaging but it is on the
manufacturer's website 7 andperhaps the dosage
warnings to the consumer should be stronger.8
Patients shouldbe advisedtotake no morethan 3
to 3.75 g of calcium carbonate (1.2 to 1.5 g of
elemental calcium) per day.4
DIAGNOSIS AND PATHOGENESIS
Thediagnosisofthemilkalkalisyndromedepends
on the history ofingestion ofexcess calcium and
alkali, the finding of hypercalcaemia, renal
impairment and metabolic alkalosis (of varying
severity), and the exclusion ofother causes. The
pathophysiology of the syndrome is complex.
While the increased intake ofcalcium must play
a part, the central abnormality is a reduction in
the ability ofthe kidneys to excrete calcium. As
partofthisreductionisduetothehypercalcaemia
itself the possibility exists that a vicious circle
will develop. The reduced excretion of calcium
results both from a reduction in glomerular
filtration rate and from an increase in tubular
reabsorption of calcium due to alkalosis.
Hypercalcaemia lowers the glomerular filtration
rate directly by inducing renal vasoconstriction,
and indirectly by reducing extracellular volume.
(Stimulated calcium-sensitive receptors in the
collecting ducts cause an isotonic polyuria by
blockingtheactionofantidiuretichormone, while
similar receptors in the loop of Henle cause an
increaseinsodiumloss(admittedlyalsoincreasing
calcium loss and magnesium loss).) Further
depletionoftheextracellularvolumeoccursfrom
the vomiting which is not uncommon in the milk
alkali syndrome. Vomiting will also make worse
any metabolic alkalosis caused by excess intake
of alkali or by increased bicarbonate absorption
fromtherenaltubulesinducedbyhypercalcaemia.
Suppression of parathyroid hormone, renal
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impairmentanddrinkingmilkwilltendtoincrease
phosphate levels, and hyperphosphataemia,
hypercalcaemia, andalkalosismayleadtoectopic
calcification. Nephrocalcinosis is common in
chronic milk alkali syndrome (although it may
not be obvious on plain radiography) and can
resultinpermanentrenal damage. Theextentand
reversibility of the renal failure depend on the
durationandseverityofthemilkalkalisyndrome.
Some residual renal impairment occurs in many
cases. Itdidnotoccurin this case due tothe short
duration of the illness.
The production of parathyroid hormone is
regulated by calcium-sensitive receptors on the
parathyroid chiefcells and varies inversely with
the plasma ionised calcium level. It might be
expectedthatwithhypercalcaemiatheproduction
ofparathyroidhormonewouldfallandtheplasma
level would be suppressed. In our patient the
parathyroid hormone level at presentation was
towards the lower limit of normal but was not
suppressed. The reason for this is not clear but it
has been seen before.4 Alkalosis does reduce the
level of ionised calcium and perhaps the
stimulation of the calcium-sensitive receptors
was less thanexpected. Beall and Scofield found
rebound hyperparathyroidism in two of seven
patients with the milk alkali syndrome treated
with saline diuresis.4 The increase inparathyroid
hormone followed hypocalcaemia in both cases.
Intheonepatientforwhomdetails weregiventhe
maximum decrease in calcium occurred onday 4
andthemaximumriseinparathyroidhormone on
day 8. They considered this rebound might be
uniquetothemilkalkalisyndromeandsuggested
thatitwas duetothe absence ofany forcedriving
the calcium up once excess intake was stopped
and rehydration started. Our patient also was
found to have arebound in parathyroid hormone
following treatmentbutthepeakoccurred onday
25 and hypocalcaemia was not demonstrated.
She received disodium pamidronate as well as
saline and while pamidronate does not affect
parathyroid hormone release from chief cells in
vitro,9 itdoes cause arise inparathyroidhormone
when given to patients with Paget's disease,'0
malignancy-associated hypercalcaemia 11 or
hyperparathyroidism.'2 This rise (which peaks
around day 7) is associated with a fall in calcium
andpresumably iscausedbyit. Pamidronate may
have caused the rise in parathyroid hormone in
our case although the longer time to peak level is
unexplained. Bisphosphonates act by inhibiting
osteoclastic bone reabsorption and have been
found to be useful in hypercalcaemia due to
malignancy'1 or hyperparathyroidism.12 As this
reabsorption is not thought to be excessive in the
milk alkali syndrome, it is unlikely that the
pamidronate helped our patient. Most cases of
milk alkali syndrome begin to respond within 24
to 48 hours oftreatment with intravenous saline
andtheelimination ofcalcium-containing alkali.
It is common to administer a loop diuretic with
the saline although this maynotbe very effective
in the presence of renal failure. Haemodialysis
may occasionally be required.
CONCLUSION
The incidence of the milk alkali syndrome may
be increasing due to increased use of calcium
carbonate. Theelderlyandthosewithco-existing
disease will be more at risk. Most patients show
a substantial improvement inrenal function with
treatment. The diagnosis can be missed if a
detailedhistoryofcalciumandalkali ingestionis
not elicited. Full details ofall medication should
be obtained whether prescribed or not as
physicians and patients are often unaware that
many non-prescription medications contain
calcium and alkali.
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